Skip to main content
Clinical Trials/KCT0008055
KCT0008055
Completed
未知

A 12 week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of Lactobacillus plantarum LMT1-48 on Reducing Body Fat

Global Medical Research Center0 sites120 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Endocrine, nutritional and metabolic diseases
Sponsor
Global Medical Research Center
Enrollment
120
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 18, 2023
Last Updated
2 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) A person who is 19 years of age or older and under 70 years of age
  • 2\) Those with a body mass index (BMI) of 25 kg/m² or more and less than 30 kg/m² for visit 1 and visit 2
  • 3\) A person who agrees to participate in the human body application test and prepares a written consent form before the human body application test begins

Exclusion Criteria

  • 1\) Serious cardiovascular system, immune system, respiratory system, gastrointestinal/hepatic and biliary tract, kidney and urinary system, nervous system, mental,
  • A person who is currently being treated for infectious diseases, etc. (However, he/she may participate in the test at the discretion of the tester considering the condition of the person subject to the human body application test)
  • 2\) Those diagnosed with cancer within 5 years as of Visit 1 (excluding thyroid cancer, early cervical cancer (endothelial cancer))
  • 3\) Within 1 month (30 days) of visit 1, weight\-affecting drugs (such as appetite suppressants, liposuction inhibitors, GLP\-1 receptor agonists), psychiatric drugs such as depression and schizophrenia, beta\-blockers, diuretics, contraceptives, thyroid hormones), hyperlipidemia drugs (including omega3\), health\-controlled, phytosanitary and dietary supplements
  • 4\) A person who has administered antibiotics and intestinal medications within two weeks as of Visit 1
  • 5\) A person who has administered or ingested probiotics, prebiotics, and lactobacillus products continuously (more than 4 times a week) within 2 weeks as of Visit 1
  • 6\) A person who has undergone obesity surgery within one year based on visit 1
  • 7\) Patients with uncontrolled hypertension (systolic blood pressure of 160 mmHg or more or diastolic blood pressure of 100 mmHg or more, measured after stabilization for 10 minutes)
  • 8\) Diabetes patients who have an empty stomach blood sugar of 126 mg/dL or higher or who are taking anti\-diabetic drugs (e.g., oral hypoglycemic drugs, insulin, etc.)
  • 9\) Those with a TSH of not more than 0\.1 µIU/mL or not more than 10 µIU/mL

Outcomes

Primary Outcomes

Not specified

Similar Trials